C12N2770/14023

MODIFIED VIRAL THERAPEUTICS AND USES THEREOF
20230038487 · 2023-02-09 ·

Disclosed herein, in certain embodiments, are engineered virus-like particles and compositions that comprise an oligodeoxynucleotide (ODN) for the treatment of a disease or condition. In some embodiments, also disclosed herein are methods of inducing phagocytosis of a target cell and methods of immune modulation.

Covalently fused viral coat proteins for the display of target molecules

A fusion protein comprising a target protein, a first recombinant viral coat protein, a second recombinant viral coat protein and a first linkage peptide is provided. The target protein is at N-terminus of the first recombinant viral coat protein. The first recombinant viral coat protein is linked to N-terminus of the first linkage peptide. The second recombinant viral coat protein is linked to C-terminus of the first linkage peptide. The first and second recombinant viral coat proteins are derived from the coat protein (CP) of alfalfa mosaic virus (AIMV). The fusion protein may further comprise a second linkage peptide between the target protein and the first recombinant viral coat protein. The fusion protein may form a virus like particle (VLP). The target protein may be displayed on the surface of the VLP. Also provided are methods for producing the fusion protein and the VLP as well as the uses of the fusion protein and/or the VLP.

TREATMENT OF INSECT BITE HYPERSENSITIVITY
20220354946 · 2022-11-10 ·

The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of insect bite 5 hypersensitivity of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating insect bite hypersensitivity of equine mammals, preferably of horses.

MODIFIED VIRUS-LIKE PARTICLES OF CMV
20170312371 · 2017-11-02 · ·

The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.

MODIFIED VIRUS-LIKE PARTICLES OF CMV
20220305131 · 2022-09-29 ·

The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.

Virus-enabled targeted vector for imaging
11202841 · 2021-12-21 · ·

A multi-chromophore virus particle is constructed by covalent binding of chromophores and provides super-radiant behavior. A virus-enabled targeted vector is provided for imaging with qualitatively different optical emission properties from state-of-the-art agents. Bright emission is obtained through quantum coherence, which in turn is facilitated by the symmetry of the virus shell. In an exemplary embodiment the targeted vector is used in laser-guided surgery, specifically for the treatment of in brain cancer.

COVID ASSAY CONTROLS
20230272351 · 2023-08-31 ·

Provided herein is a synthetic viral particle that positive control for COVID assays, along with methods for making and using the viral particle.

Modified virus-like particles of CMV
11324836 · 2022-05-10 · ·

The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.

Treatment of insect bite hypersensitivity

The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of insect bite hypersensitivity of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating insect bite hypersensitivity of equine mammals, preferably of horses.

PLANT VIRAL NUCLEIC ACID DELIVERY PARTICLES AND USES THEREOF
20220313618 · 2022-10-06 ·

A nanoparticle includes a plant virus or plant virus like particle (VLP), an exogenous therapeutic nucleic acid encapsulated within the plant virus or plant VLP, and one or more fusogenic peptides or cell penetrating peptides conjugated to an exterior surface of the plant virus or plant VLP.